The Second Wind Foundation Donates $5,000 To Massachusetts General Hospital To Further Research On Pulmonary Fibrosis

Second Wind Foundation for Pulmonary Fibrosis President Ron Geoffroy and Dr Tager Others in the photo: Katharine Black, MD Rachel Knipe, MD David Lagares, MD  Neil Ahluwalia, MD  Flavia Castelino, MD  Veronica Pace, MD Paula Grasberger, MD

Second Wind Foundation for Pulmonary Fibrosis President Ron Geoffroy and Dr Tager
Others in the photo: Katharine Black, MD Rachel Knipe, MD David Lagares, MD Neil Ahluwalia, MD Flavia Castelino, MD Veronica Pace, MD Paula Grasberger, MD

(Manchester, NH) This week Ron Geoffroy, President of the Second Wind Foundation for Pulmonary Fibrosis, delivered a check for $5,000 to Dr Tager, who accepted the check on behalf of the Massachusetts General Hospital. Massachusetts General Hospital is well known throughout the country for their cutting edge research on Pulmonary Fibrosis.

Pulmonary Fibrosis is a rare lung disease that creates scar tissue inside the lungs, making it harder and harder to breathe.   Pulmonary Fibrosis currently effects more than 500,000 people in the US.

“We are deeply appreciative of all that the Second Wind Foundation is doing to raise awareness of pulmonary fibrosis and to advance our research in pursuit of new treatments for this devastating disease,” said Dr Tager. “Philanthropic support is vital to ensuring that our team of researchers at Mass General can explore multiple avenues toward discoveries that can improve the lives of countless patients and their families. I can’t thank Ron, the board members and all of the Second Wind Foundation supporters enough for their generosity.”

Second Wind Foundation for Pulmonary Fibrosis President Ron Geoffroy and Dr Tager

Second Wind Foundation for Pulmonary Fibrosis President Ron Geoffroy and Dr Tager

“In particular, our laboratory will use the funds so generously provided by the Second Wind Foundation to support the research we do with the diseased lungs of patients with pulmonary fibrosis who receive lung transplants.  After these lungs are removed as part of the transplant procedure, they provide us with an invaluable window into how pulmonary fibrosis progresses to the point where it becomes life-threatening,” concluded Dr. Tager.

“We are proud to be presenting this $5,000 check to Massachusetts General Hospital for their work and support for those who suffer from Pulmonary Fibrosis,” said Ron Geoffroy, President of the Second Wind Foundation for Pulmonary Fibrosis.  “One day, we will find a cure for Pulmonary Fibrosis, and it could be from research being conducted at Massachusetts General Hospital.”

This is the third year in a row that the Second Wind Foundation has donated to Massachusetts General Hospital specifically for research on Pulmonary Fibrosis.  The Second Wind Foundation was able to make this donation thanks to generous private donations and fundraisers like our annual “Hockey Night” fundraiser with the Manchester Monarchs coming up on Feb. 7th.  To purchase tickets to the Manchester Monarchs “Pink in the Rink” hockey game through the Second Wind Foundation go to http://secondwindforpf.com/2014/10/join-us-for-hockey-night-fundraiser-with-the-manchester-monarchs/.

For more information on the Second Wind Foundation for Pulmonary Fibrosis go to http://secondwindforpf.com/.

 

The Second Wind Foundation For Pulmonary Fibrosis

Ron and MaryLou Geoffroy started The Second Wind Foundation for Pulmonary Fibrosis in 2010 after MaryLou was diagnosed with Pulmonary Fibrosis.  They struggled to find information and support for people with PF. Ron and MaryLou started the foundation because they wanted to help raise awareness and money to support continued research for this unknown disease.  The Second Wind Foundation for Pulmonary Fibrosis continues to educate the public about this rare but deadly disease, raise money for research and to help families suffering with PF.

Ron Geoffroy continues to lead the Second Wind Foundation in loving memory of his late wife.

RELEASE: The Second Wind Foundation For Pulmonary Fibrosis Teams Up With The Manchester Monarchs For Hockey Night Fundraiser

cropped-Second-Wind-Foundation-Final-Copy-1-e1359993411518.jpgImmediate Release
Contact Ron Geoffroy
Info@SecondWindforPF.com

(Auburn, NH) – The Second Wind Foundation for Pulmonary Fibrosis has once again teamed up with the Manchester Monarchs for a hockey night fundraiser.

The Second Wind Foundation is selling tickets to the Monarchs annual “Pink In The Rink” game on February 7th , against the Providence Bruins. Tickets can be purchased for $20 dollars with $8.00 from each ticket going directly to the Second Wind Foundation for Pulmonary Fibrosis.

The “Pink in the Rink” night is a very special night for the Manchester Monarchs and Catholic Medical Center, as a portion of each ticket sold will be given directly to CMC. Last year the Monarchs and CMC raised over $10,000 in ticket sales and raffles. If you get your tickets from the Second Wind Foundation you will be able to support two great causes.

Pulmonary Fibrosis is a rare lung disease that creates scar tissue inside the lungs, making it harder and harder to breathe.   Pulmonary Fibrosis currently effects more than 500,000 people in the US.

The annual fundraiser brings in much needed donations that are used to fund ongoing research, like the “Pirfenidone” drug trials. The donations also go to our new “Breathe Easy” program that provides monetary support for families who are suffering with Pulmonary Fibrosis. The Second Wind Foundation provides qualifying families with gas cards to ease the cost of multiple visits to pulmonary specialists.

This year the Second Wind Foundation donated $5,000 to the Massachusetts General Hospital for their ground-breaking research on Pulmonary Fibrosis.

“Our annual hockey night fundraiser is one of my favorite events,” said Ron Geoffroy, President of the Second Wind Foundation for Pulmonary Fibrosis. “This is a great opportunity for families to enjoy professional level hockey while supporting two great causes.”

For more information and to purchase tickets go to http://secondwindforpf.com/.

The Second Wind Foundation For Pulmonary Fibrosis 

Ron and MaryLou Geoffroy started The Second Wind Foundation for Pulmonary Fibrosis in 2010 after MaryLou was diagnosed with Pulmonary Fibrosis. They struggled to find information and support for people with PF. Ron and MaryLou started the foundation because they wanted to help raise awareness and money to support continued research for this unknown disease. The Second Wind Foundation for Pulmonary Fibrosis continues to educate the public about this rare but deadly disease, raise money for research and to help families suffering with PF. 

Ron Geoffroy continues to lead the Second Wind Foundation in loving memory of his late wife.

New Drug (Nintedanib) Can Slow Pulmonary Fibrosis Progression

We at the Second Wind Foundation for Pulmonary Fibrosis, work to raise awareness about this rare but deadly disease.  We are also raising money to help fund research projects similar to this one below.  Come join us at our annual charity night with the Manchester Monarchs.  This year it will be on Feb 7th for “Pink in the Rink.”

Below is a press release from Boehringer Ingelheim a european drug manufacturer who is working on a drug that is showing real progress in slowing the progression of IPF in trials.

Nintedanib* receives positive CHMP opinion in
European Union for the treatment of IPF

Boehringer Ingelheim today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for nintedanib* (suggested brand name OFEV®) for the treatment of patients with idiopathic pulmonary fibrosis (IPF). Results from the Phase III INPULSIS® trials published in the New England Journal of Medicine in May showed that nintedanib* significantly slowed disease progression in a broad range of patients with IPF**.1 The opinion comes after the recent Food and Drug Administration (FDA) approval of nintedanib* for the treatment of IPF.

“Boehringer Ingelheim welcomes the decision by the CHMP. There has been a high unmet need for effective treatments that can slow disease progression in IPF. We look forward to making nintedanib available soon to patients with IPF in the EU” said Professor Klaus Dugi Chief Medical Officer Boehringer Ingelheim.

IPF is a debilitating and fatal lung disease with a median survival of 2–3 years after diagnosis.2 It causes progressive scarring of the lungs resulting in continual and irreversible deterioration in lung function and difficulty breathing.3

“This decision is very encouraging as patients with IPF currently have very limited treatment options” said INPULSIS® study investigator Professor Luca Richeldi Professor of Respiratory Medicine Chair of Interstitial Lung Disease at the University of Southampton United Kingdom. “For the first time we have a drug that has consistently met the primary endpoint in two large Phase III trials confirming the results of the Phase II trial.”

The CHMP’s positive opinion is based on pivotal data from the replicate Phase III INPULSIS® trials involving 1066 patients from 24 countries. INPULSIS® results showed that nintedanib* slowed disease progression by reducing the annual rate of decline in lung function by 50% in a broad range of IPF patient types: this included patients with early disease (forced vital capacity (FVC) >90% pred) limited radiographic fibrosis (no honeycombing) on high resolution computed tomography (HRCT) and those with emphysema.1 As well nintedanib* significantly reduced the risk of adjudicated acute exacerbations by 68%.1 This can be crucial given that approximately 50% of patients hospitalised for an acute IPF exacerbation die during hospitalisation.4

Nintedanib* in IPF has been granted accelerated assessment by the EMA. Nintedanib* one capsule twice a day is the first treatment for IPF that has consistently demonstrated a significant reduction in the decline in lung function and has a manageable side effect profile.1 More than 90% of eligible patients who participated in the INPULSIS® trials opted to continue with nintedanib* treatment as part of an open-label extension trial.5

*Nintedanib is currently being assessed by the European Medicines Agency (EMA) and other regulatory organisations worldwide

**INPULSIS® recruited a broad range of patient types – similar to those seen in clinical practice including patients with early disease (FVC > 90% pred) no honeycombing on HRCT and/or concomitant emphysema

‡Adjudicated exacerbations’ was a pre-specified sensitivity analysis in the pooled data set. Time to first Investigator-reported exacerbation was a secondary endpoint which was met in TOMORROW and INPULSIS®-2 but not in INPULSIS®-1

~ENDS~

Please click on the link below for ‘Notes to Editors’ and ‘References’:http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2014/21_november_2014_ipf.html

 

Great Weather Predicted For This Weekends “Give A Gift Of Breath” Motorcycle Ride

Motorcycle (Maurice CC FLIKR)Motorcycle Riders Cruise Through Central New Hampshire For A Good Cause 

The Second Wind Foundation for Pulmonary Fibrosis Hosts annual “Give A Gift Of Breath” ride to help raise money for patient support and research.

(Hooksett,NH) This Saturday is expected to be a perfect September day in New Hampshire, and riders from all across the region are expected to take part in the “Give A Gift Of Breath” motorcycle ride to benefit The Second Wind Foundation for Pulmonary Fibrosis.

“Saturday is predicted to be a perfect day for a motorcycle ride,” said Ron Geoffroy, President of the Second Wind Foundation for Pulmonary Fibrosis.   “With the addition of live music by the Rik-Sha Band, and food provided by the Puritan Backroom, this could be our biggest ride to date.”

Pulmonary Fibrosis is a rare lung disease that creates scar tissue inside the lungs, making it harder and harder to breathe.   Pulmonary Fibrosis currently effects more than 500,000 people in the US.

The annual ride brings in much needed donations that are used to fund ongoing research, like the “Pirfenidone” drug trials.  The donations also go to our new “Breathe Easy” program that provides monetary support for families who are suffering with Pulmonary Fibrosis.  The Second Wind Foundation provides qualifying families with gas cards to ease the cost of multiple visits to pulmonary specialists.

The ride kicks off from the Plumbers and Pipefitters Hall, 161 Londonderry Turnpike, Hooksett, NH at 10:30 am.  The cost is $25 per motorcycle, and $10 per additional rider. Registration starts at 8 am.

After the two-hour scenic New Hampshire ride, feast on lunch provided by The Puritan Backroom, and enjoy live rockabilly-blues music from the Rik-Sha Band.  There will also be silent auctions and raffles for great prizes from local restaurants and shops.

“We look forward to seeing everyone Saturday morning for the Give A Gift of Breath motorcycle ride,” added Geoffroy.


Bikes and Riders



The Second Wind Foundation For Pulmonary Fibrosis Proudly Announces The “Breathe Easy” Program To Help Families Suffering From Pulmonary Fibrosis

For Immediate Release

The Second Wind Foundation For Pulmonary Fibrosis Proudly Announces The “Breathe Easy” Program To Help Families Suffering From Pulmonary Fibrosis 

The Second Wind Foundation to provide gas cards to families who are suffering from Pulmonary Fibrosis.

Filling Gas Tank (KOMUnews CC Flikr)Auburn, NH – The Second Wind Foundation for Pulmonary Fibrosis proudly announces the start of a new program designed to help families who are suffering from Pulmonary Fibrosis.

Pulmonary Fibrosis is a rare lung disease that creates scar tissue inside the lungs, making it harder and harder to breathe.   Pulmonary Fibrosis currently effects more than 500,000 people in the US.  After being diagnosed with Pulmonary Fibrosis, patients must meet with their doctors regularly to monitor their condition.  The increase in doctor visits, home healthcare, and oxygen tanks put a significant financial strain on patients and their families.

Ron and Marylou Geoffroy started the Second Wind Foundation for Pulmonary Fibrosis, after Marylou was diagnosed with Pulmonary Fibrosis.

“As Marylou’s condition deteriorated, we were traveling to Boston for doctors appointments a few times a month,” said Ron Geoffroy President of the Second Wind Foundation for Pulmonary Fibrosis. “This is exactly why we started the ‘Breathe Easy’ program, to give some monetary support to families suffering from Pulmonary Fibrosis.”

To help families deal with the financial strains that a chronic disease can have, the Second Wind Foundation for Pulmonary Fibrosis created the Breathe Easy program to provide $50 gas cards to qualified recipients.

The Breathe Easy program is open to anyone who suffers from Pulmonary Fibrosis or for those who are caring for someone with PF.  The Breathe Easy application can be downloaded at http://secondwindforpf.com/breathe-easy-program/.

Right now there is no cure for Pulmonary Fibrosis, and thanks to donations from the Second Wind Foundation for Pulmonary Fibrosis, new research is helping to find a cure.

To help raise money for this new program the Second Wind Foundation is hosting a charity motorcycle ride this September. The “Give A Gift Of Breath” motorcycle ride will be held on September 13th 2014 and begins at the Plumbers and Pipefitters Hall, 161 Londonderry Turnpike, Hooksett, NH.

Enjoy a scenic ride through the tree-lined roads of central New Hampshire, and then enjoy some great food courtesy of the Puritan Back Room.

Registration for the ride begins at 8:00 am with kickstands up at 10:30 a.m.  The cost is only $25 per bike and $10 for additional riders.

“The Give a Gift of Breath motorcycle ride is one of our biggest annual fundraisers for the Second Wind Foundation,” said Geoffroy. “To encourage people to sign up early for the ride, we are offering a $5 discount if you register now.”

For more information about the Second Wind Foundation for Pulmonary Fibrosis, and to register for our upcoming ride, go to http://secondwindforpf.com/.